ASCO GU 2022 - Results from #60

Viewing 61-80 of 316 articles

ASCO GU 2022: Genomic Instability Is Enriched in Localized Prostate Cancers from Men of African Ancestry

ASCO GU 2022: Predictive Factors for Effectiveness from Novel Androgen-Receptor-Axis-Targeted Agents in Patients with Metastatic Prostate Cancer

ASCO GU 2022: Correlation of the Rate of Metastasis-Free Survival with the Presence of Pathogenic Germline Genetic Mutations in Patients with Prostate Cancer at a Community Practice

ASCO GU 2022: PEARLS: A Multicenter Phase II/III Trial of Extended Field Radiotherapy for Androgen Sensitive Prostate Cancer Patients with PSMA‐avid Pelvic and Para-Aortic Lymph Nodes at Presentation

ASCO GU 2022: Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, Systematic Biopsy, and Combined Biopsy for the Diagnosis of Prostate Cancer

ASCO GU 2022: Do Prostate MRI Reports Consider Focal Therapy When Describing Diagnostic Findings? a Descriptive Review and Analysis of Concordance Among Prostate MRI Reports and Radical Prostatectomy Pathology Reports

ASCO GU 2022: Development and Validation of a Prognostic AI Biomarker Using Multi-Modal Deep Learning with Digital Histopathology in Localized Prostate Cancer on NRG Oncology Phase III Clinical Trials

ASCO GU 2022: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP1801)

ASCO GU 2022: Optimizing Management of Localized Prostate Cancer: Combined Modality Therapy in Localized Disease

ASCO GU 2022: Attainment of Early, Deep PSA Response in mCSPC: A Comparison of Patients Initiated on Apalutamide or Enzalutamide

ASCO GU 2022: Association of Functional Outcomes by Decision-Making Approach in Men with Metastatic Prostate Cancer

ASCO GU 2022: Artificial Intelligence as a Disruptive Technology in Medicine

ASCO GU 2022: An AI-Derived Digital Pathology-Based Biomarker to Predict the Benefit of ADT in Localized Prostate Cancer with Validation in NRG/RTOG 9408

ASCO GU 2022: 68Ga-PSMA PET/CT for Preoperative Lymph Nodes Staging of High-Risk Prostate Cancer

ASCO GU 2022: A Phase Ia/Ib Study of Talazoparib in Combination with Tazemetostat in mCRPC

ASCO GU 2022: Active Surveillance for Patients with Intermediate-Risk Disease: Risk vs. Benefit

ASCO GU 2022: Treatment Trends Among Men With Metastatic Castration Sensitive Prostate Cancer: Results From the US Component of an International Study

ASCO GU 2022: Management of Toxicities with Novel Systemic Therapies in Urothelial Carcinoma

ASCO GU 2022: The Future Landscape of Adjuvant and Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

ASCO GU 2022: Highlighting Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective

1
2
3
4
5
6
7
8
9
10